{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-005489","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.447240+00:00","generated_at":"2026-05-26T06:52:49.054903+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ADMA Biologics sets 2025 executive comp; CEO Grossman base $925k with equity awards","bullets":["CEO Grossman: 2025 base $925k, 2024 cash bonus $1.02M, 252,022 RSUs, 376,744 options at $16.07 strike.","COO Kestenberg: 2025 base $575k, 2024 bonus $293,625, 77,784 RSUs, 116,279 options.","CFO Tade: 2025 base $500k, 2024 bonus $254,475, 62,227 RSUs, 93,023 options.","Non-employee directors get annual equity grants of $350k (50% RSUs, 50% options) and increased committee retainers."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-005489","json":"https://secwatch.observer/filing/0001140361-25-005489.json","markdown":"https://secwatch.observer/filing/0001140361-25-005489.md","text":"https://secwatch.observer/filing/0001140361-25-005489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125005489/0001140361-25-005489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125005489/ef20044064_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:52:49.054903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}